Michael Sporn believes the best bet for controlling cancer is to pick up the warning signs and nip it in the bud. A pot of gold awaits any drugs company that can come up with a Lipitor for cancer, says Sporn, and easy-to-use biomarkers would already be on the market had one-tenth of the research dollars poured into chemotherapy been invested in proteomics.
